The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Safety run-in of a Phase II trial of CPX-351 plus pomalidomide in AML with MDS-related changes
Daniel Peters, MD, UNC School of Medicine, Chapel Hill, NC, discusses the safety run-in evaluation of a Phase II trial comparing CPX-351 plus pomalidomide to CPX-351 alone in newly diagnosed acute myeloid leukemia (AML) with myelodysplastic syndromes (MDS)-related changes. Among the nine patients enrolled so far, 6 received a pomalidomide dose of 4 mg daily, while 3 received a lower dose due to potential dose-limiting toxicities. Enrollment is ongoing, with 20 out of a planned 70 patients already accrued. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
